<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411645</url>
  </required_header>
  <id_info>
    <org_study_id>1263-300</org_study_id>
    <secondary_id>2006-005692-18</secondary_id>
    <secondary_id>SHP620-300</secondary_id>
    <nct_id>NCT00411645</nct_id>
    <nct_alias>NCT00430339</nct_alias>
  </id_info>
  <brief_title>Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate whether or not maribavir is safe and
      effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who
      have had a stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) infections remain a significant problem following various types of
      transplants that are associated with strong immunosuppressive therapy. Maribavir is a new
      oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV
      drugs. This study will test the safety and efficacy of maribavir for the prevention of CMV
      disease when given as prophylaxis for up to 12 weeks following allogeneic stem cell
      transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 6 Months Post-transplant</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of CMV Infection or EC-confirmed CMV Disease Within 6 Months Post- Transplantation</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease) were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay or (2) CMV DNA polymerase chain reaction (PCR). CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Investigator-determined CMV Disease</measure>
    <time_frame>Through 12 months post-transplant (Day 1 to 100 days, 6 months, and 12 months post-transplant)</time_frame>
    <description>CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 100 Days Post-Transplantation</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With EC-confirmed CMV Disease Within 12 Months Post-Transplantation</measure>
    <time_frame>12 months post-transplant</time_frame>
    <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Acute Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Through 6 months post-transplant (Days 1 to 100 and 6 months post-transplant)</time_frame>
    <description>Analysis of acute GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for acute GVHD. The percentage reported is for the occurrence of any grade of acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Chronic Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Through 6 months post-transplant (Days 1 to 100 and 6 months post-transplant)</time_frame>
    <description>Analysis of chronic GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for chronic GVHD. The percentage reported is for the occurrence of any grade of chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Within 12 Months Post-Transplantation</measure>
    <time_frame>Through 12 months post-transplant (Days 1 to 100, 6 months, and 12 months post-transplant)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Maribavir During Treatment</measure>
    <time_frame>12 hours post-dose after 1 and 4 weeks of treatment</time_frame>
    <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Maribavir Metabolite VP 44469 During Treatment</measure>
    <time_frame>12 hours post-dose after 1 and 4 weeks of treatment</time_frame>
    <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of VP 44469, a metabolite of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">681</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maribavir</intervention_name>
    <description>100 mg twice daily for up to 12 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>twice daily for up to 12 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic stem cell transplant recipient

          -  Recipient or donor CMV seropositive

          -  Have transplant engraftment

          -  Able to swallow tablets

        Exclusion Criteria:

          -  CMV organ disease

          -  HIV infection

          -  Use of other anti-CMV therapy post-transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A Villano, MD</last_name>
    <role>Study Director</role>
    <affiliation>ViroPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas Myeloma Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusettes General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital,Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeanes Hospital - Temple</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latter Day Saints Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan, Department of Hematology</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St,Luc Dept Hematology</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart -Tilman Department of Medicine, Hematology</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Campus</name>
      <address>
        <city>Ottawa,</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Enfant Jesus</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hopital</name>
      <address>
        <city>Lyon, Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes, Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Clinic Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover, Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln, Clinic I for internal Medicine</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pescara Hospital</name>
      <address>
        <city>Pescara</city>
        <zip>65123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bianchi-Melacrino-Morelli Hospital</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duran i Reynals Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>E-37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital,Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset, Dept Hematology</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2006</study_first_submitted>
  <study_first_submitted_qc>December 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <results_first_submitted>May 15, 2015</results_first_submitted>
  <results_first_submitted_qc>May 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <disposition_first_submitted>July 21, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 21, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 24, 2014</disposition_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <keyword>SCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Maribavir 100 mg BID</title>
          <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator/Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Maribavir 100 mg BID</title>
          <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
            <count group_id="B2" value="454"/>
            <count group_id="B3" value="681"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="13.1"/>
                    <measurement group_id="B2" value="49" spread="12.5"/>
                    <measurement group_id="B3" value="49" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation</title>
        <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>6 months post-transplant</time_frame>
        <population>The Intent-to-Treat (ITT) population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation</title>
          <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The Intent-to-Treat (ITT) population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.789</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.902</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.424</ci_lower_limit>
            <ci_upper_limit>1.920</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 6 Months Post-transplant</title>
        <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>6 months post-transplant</time_frame>
        <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 6 Months Post-transplant</title>
          <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pp65 antigenemia assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV DNA PCR assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pp65 antigenemia or CMV DNA PCR assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initiation of anti-CMV therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of pp65 antigenemia assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.721</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.515</ci_lower_limit>
            <ci_upper_limit>1.008</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of CMV DNA PCR assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.979</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.697</ci_lower_limit>
            <ci_upper_limit>1.375</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of pp65 antigenemia or CMV DNA PCR assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.289</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.838</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.606</ci_lower_limit>
            <ci_upper_limit>1.161</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of initiation of anti-CMV therapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.493</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.891</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.640</ci_lower_limit>
            <ci_upper_limit>1.239</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of CMV Infection or EC-confirmed CMV Disease Within 6 Months Post- Transplantation</title>
        <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease) were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay or (2) CMV DNA polymerase chain reaction (PCR). CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>6 months post-transplant</time_frame>
        <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of CMV Infection or EC-confirmed CMV Disease Within 6 Months Post- Transplantation</title>
          <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease) were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay or (2) CMV DNA polymerase chain reaction (PCR). CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="5" upper_limit="22"/>
                    <measurement group_id="O2" value="22" lower_limit="6" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <p_value_desc>The p-value from Wald Chi-Square test for treatment effect.</p_value_desc>
            <method>Wald Chi-squared</method>
            <param_type>Adjusted hazard ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Maribavir versus placebo; based on Cox’s proportional hazards regression model: time = recipient CMV serostatus (R+ or R-) + transplant type (myeloablative or non-myeloablative/reduced intensity) + treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Investigator-determined CMV Disease</title>
        <description>CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>Through 12 months post-transplant (Day 1 to 100 days, 6 months, and 12 months post-transplant)</time_frame>
        <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Investigator-determined CMV Disease</title>
          <description>CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days post-tranplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 100 days post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 6 months post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 12 months post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 100 Days Post-Transplantation</title>
        <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>100 days post-transplant</time_frame>
        <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CMV Infection or EC-confirmed CMV Disease Within 100 Days Post-Transplantation</title>
          <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pp65 antigenemia assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMV DNA PCR assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pp65 antigenemia assay or CMV DNA PCR assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initiation of anti-CMV therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EC-confirmed disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of pp65 antigenemia assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.669</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.474</ci_lower_limit>
            <ci_upper_limit>0.946</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of CMV DNA PCR assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.878</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.617</ci_lower_limit>
            <ci_upper_limit>1.247</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of pp65 antigenemia assay or CMV DNA PCR assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.772</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.555</ci_lower_limit>
            <ci_upper_limit>1.075</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of initiation of anti-CMV therapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.731</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.521</ci_lower_limit>
            <ci_upper_limit>1.026</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of EC-confirmed disease</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.332</ci_lower_limit>
            <ci_upper_limit>2.508</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With EC-confirmed CMV Disease Within 12 Months Post-Transplantation</title>
        <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
        <time_frame>12 months post-transplant</time_frame>
        <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With EC-confirmed CMV Disease Within 12 Months Post-Transplantation</title>
          <description>All investigator-determined cases of CMV disease (i.e., CMV infection or CMV organ disease), were adjudicated by an independent, blinded EC. CMV infection was assessed by (1) pp65 antigenemia assay; (2) CMV DNA polymerase chain reaction (PCR); (3) either assay (pp65 antigenemia or CMV DNA PCR); or (4) initiation of anti-CMV therapy. CMV infection was defined as: CMV infection detected by a positive result from a CMV laboratory assay from at least one central laboratory assay (pp65 antigenemia or CMV DNA PCR assay in plasma) and fever &gt;/=38 °C on &gt;/=2 occasions &gt;/=24 hours apart within a 7-day period and at least one of the following: new or increased malaise, two successive measurements of leucopenia (white blood cell [WBC] count &lt;3500/mm3 or a WBC count decrease of 20% if the cell count prior to onset of clinical symptoms was &gt;4000/mm3) &gt;/=24 hours apart, atypical lymphocytosis &gt;/=5%, and thrombocytopenia. CMV organ disease was defined as described by Ljungman et al., 2002.</description>
          <population>The ITT population, defined as all participants who were randomized to one of the therapy groups, regardless of whether the participant received study drug or had any post-baseline evaluations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="454"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 12 months post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R-) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.835</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.411</ci_lower_limit>
            <ci_upper_limit>1.693</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
        <description>Analysis of acute GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for acute GVHD. The percentage reported is for the occurrence of any grade of acute GVHD.</description>
        <time_frame>Through 6 months post-transplant (Days 1 to 100 and 6 months post-transplant)</time_frame>
        <population>The ITT Safety (ITT-S) population, defined as participants in the ITT population who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
          <description>Analysis of acute GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for acute GVHD. The percentage reported is for the occurrence of any grade of acute GVHD.</description>
          <population>The ITT Safety (ITT-S) population, defined as participants in the ITT population who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 100 days post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7808</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R -) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.754</ci_lower_limit>
            <ci_upper_limit>1.457</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 6 months post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6946</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R -) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.771</ci_lower_limit>
            <ci_upper_limit>1.479</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Chronic Graft-Versus-Host Disease (GVHD)</title>
        <description>Analysis of chronic GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for chronic GVHD. The percentage reported is for the occurrence of any grade of chronic GVHD.</description>
        <time_frame>Through 6 months post-transplant (Days 1 to 100 and 6 months post-transplant)</time_frame>
        <population>The ITT-S population, defined as participants in the ITT population who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Chronic Graft-Versus-Host Disease (GVHD)</title>
          <description>Analysis of chronic GVHD was based on reported adverse events that mapped to the relevant MedDRA dictionary terms for chronic GVHD. The percentage reported is for the occurrence of any grade of chronic GVHD.</description>
          <population>The ITT-S population, defined as participants in the ITT population who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 100 days post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6304</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R -) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.592</ci_lower_limit>
            <ci_upper_limit>2.375</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of 6 months post-transplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1019</p_value>
            <p_value_desc>The p-value is from the Cochran-Mantel-Haenszel test, adjusting for recipient CMV serostatus (R+ or R -) and transplant type (myeloablative or non-myeloablative/reduced intensity).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.726</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.495</ci_lower_limit>
            <ci_upper_limit>1.066</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel odds ratio for maribavir versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Within 12 Months Post-Transplantation</title>
        <time_frame>Through 12 months post-transplant (Days 1 to 100, 6 months, and 12 months post-transplant)</time_frame>
        <population>The ITT-S population, defined as participants in the ITT population who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Within 12 Months Post-Transplantation</title>
          <population>The ITT-S population, defined as participants in the ITT population who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100 days post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Maribavir During Treatment</title>
        <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
        <time_frame>12 hours post-dose after 1 and 4 weeks of treatment</time_frame>
        <population>The pharmacokinetic (PK) population, defined as those participants in the ITT population from whom plasma samples were drawn, tested for maribavir concentrations, and complete, evaluable PK data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Maribavir During Treatment</title>
          <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
          <population>The pharmacokinetic (PK) population, defined as those participants in the ITT population from whom plasma samples were drawn, tested for maribavir concentrations, and complete, evaluable PK data were available.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week post-dose, n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post-dose, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Maribavir Metabolite VP 44469 During Treatment</title>
        <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of VP 44469, a metabolite of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
        <time_frame>12 hours post-dose after 1 and 4 weeks of treatment</time_frame>
        <population>The PK population, defined as those participants in the ITT population from whom plasma samples were drawn, tested for maribavir concentrations, and complete, evaluable PK data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Maribavir 100 mg BID</title>
            <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Maribavir Metabolite VP 44469 During Treatment</title>
          <description>Pharmacokinetic (PK) profile sampling was performed to evaluate plasma concentrations of VP 44469, a metabolite of Maribavir. During the study drug administration period, blood samples for this purpose were collected on Day 7 (Week 1) and at Week 4. Every effort was made to ensure that doses were administered 12 hours apart on the day before and on the day of PK sampling. Permissible assessment windows for PK profile sampling purposes were +/- 3 days and +/- 5 days for the 1- and 4- week samples, respectively. Samples were analyzed by a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method. The validated lower limit of quantitation (LLOQ) in plasma was 0.2 μg/mL.</description>
          <population>The PK population, defined as those participants in the ITT population from whom plasma samples were drawn, tested for maribavir concentrations, and complete, evaluable PK data were available.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week post-dose, n=63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post-dose, n=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events are reported for the ITT-S population, defined as participants in the ITT population who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo twice daily (BID) for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Maribavir 100 mg BID</title>
          <description>Participants received maribavir 100 mg twice daily (BID) for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Aplasia Pure Red Cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Haemolytic Uraemic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Leukaemia Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lymphoproliferative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myeloma Recurrence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Relapse of underlying disease</sub_title>
                <description>Relapse of underlying disease includes the following MedDRA Preferred Terms: &quot;Leukemia recurrent, myeloma recurrence, non-Hodgkin’s lymphoma recurrent, and myelodysplastic syndrome&quot;</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thrombotic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Eosinophilic Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Caliciviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Helicobacter Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lactose Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Peritonitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rectal Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Venoocclusive Liver Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Chronic Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acinetobacter Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Adenovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bk Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Catheter Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Central Line Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Enterococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Enterococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Epstein-Barr Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Escherichia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Herpes Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Human Herpesvirus 6 Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Human Polyomavirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Klebsiella Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Klebsiella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia Cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pseudomonal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Salmonella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Serratia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Streptococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blood Stem Cell Transplant Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Incision Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Therapeutic Agent Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Blood Uric Acid Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Failure To Thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Muscle Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myopathy Steroid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Staphylococcal Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Extrapyramidal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Meningitis Aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Meningitis Enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lung Infection Pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Parainfluenzae Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia Fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pulmonary Alveolar Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Skin Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="408" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bk Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

